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Abstract 
Background: VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intracellular anti-
gen termed cytoskeleton-linking membrane protein 63. rER is typically found in viable tumour cells and is abundant 
in osteosarcoma cells. The aim of this study was to determine the diagnostic and prognostic utility of VS38c in the 
histological assessment of osteosarcoma and other bone tumours/tumour-like leisons.
Methods: Immunohistochemical staining with VS38c was carried out on formalin-fixed specimens of osteosarcoma 
(pre/post-chemotherapy) and a wide range of benign and malignant bone lesions. In addition, VS38c staining of cul-
tures of MG63 and Sa0S2 osteosarcoma cell cultures. (±cisplatin and actinomycin D-treatment) was analysed.
Results: VS38c strongly stained tumour cells in all low-grade and high-grade osteosarcomas and in undifferentiated 
sarcomas and high-grade chondrosarcomas. There was little or no VS38c staining of low-grade chondrosarcomas or 
chordomas and variable staining of Ewing sarcomas. Osteoblasts in benign bone-forming tumours and mononuclear 
stromal cells in chondroblastomas, giant cell tumours and non-ossifying fibromas strongly stained for VS38c. VS38c 
staining was absent in cisplatin and actinomycin D treated Sa0S2 and MG63 cells. In specimens of osteosarcoma post-
neoadjuvant therapy, VS38c staining was absent in most morphologically necrotic areas of tumor although some cells 
with pyknotic nuclei stained for VS38c in these areas. Most tumour cells exhibiting atypical nuclear forms were not 
stained by VS38c.
Conclusions: Our findings show that VS38c is a sensitive but not specific diagnostic marker of osteosarcoma. Stain-
ing with VS38c identifies viable osteosarcoma cells, a feature which may be useful in the assessment of percentage 
tumour necrosis post-neoadjuvant chemotherapy.
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Background
VS38c is a monoclonal antibody that recognises an intra-
cellular antigen identified as the rough endoplasmic 
reticulum (rER) cytoskeleton-linking membrane pro-
tein P63 (CLIMP 63) which has also been termed P63 
and cytoskeletal-associated protein 4 [1]. CLIMP-63 is 
a stable, abundant rER protein that plays a role in pro-
tein transport. The VS38c monoclonal antibody strongly 
stains immunoglobulin-producing plasma cells and facil-
itates the immunohistochemical diagnosis of myeloma 
[2, 3]. VS38c staining of tumour cells in neuroendocrine 
carcinoma, melanoma and osteosarcoma has also been 
reported [4–7]. A common feature of all tumour cells 
that stain with VS38c is that they ultrastructurally con-
tain numerous cytoplasmic ribosomes and abundant rER.
Regular protein production is a functional characteris-
tic of viable cells, and loss or inactivation of ribosomes 
and rER has been noted in necrotic tumour cells [8, 9]. 
Several types of cell death involve changes in ER [10, 11], 
and ER stress has been shown to play a role in the necro-
sis of osteosarcoma cells [12–14]. Osteosarcomas are 
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usually treated pre-operatively by a course of neoadju-
vant chemotherapy with assessment of the response eval-
uated by determining histologically the extent of necrosis 
in the resected tumour specimen [15–19]; this percent-
age measure of tumour necrosis provides important 
prognostic information and gives a guide to as to whether 
adjuvant chemotherapy is required. Osteosarcoma cells 
can exhibit nuclear abnormalities post-chemotherapy 
and it is not certain whether such cells are viable or apop-
totic in this context [20–26]. There are no formal mor-
phological criteria that can be used to determine whether 
an osteosarcoma cell is viable or not and it can be diffi-
cult to assess accurately the extent of necrosis in an oste-
osarcoma specimen.
In this study, we have sought to determine the diagnos-
tic and prognostic utility of VS38c in the assessment of 
osteosarcoma and other primary bone tumours. We have 
examined VS38c staining in a wide range of benign and 
malignant bone tumours, including osteosarcoma sub-
types, in order to assess the sensitivity and specificity of 
this marker for the diagnosis of osteosarcoma. In addi-
tion, as ER changes have been noted in necrotic tumour 
cells, and active protein production is a feature of cell 
viability, we have examined VS38c staining in osteosar-
comas that have received neoadjuvant chemotherapy in 
order to determine if expression of this marker can be 
used to identify viable tumour cells and to facilitate the 




Paraffin-embedded tissue from 178 specimens of bone 
tumours as well as specimens of normal compact and 
cancellous bone, femoral articular surface and growth 
plate, were retrieved from the files of the Nuffield Ortho-
pedic Centre Histopathology Department, Oxford 
(Table  1). 61 cases of high-grade osteosarcoma were 
analysed including 25 cases that had histology pre/post-
neoadjuvant chemotherapy. Criteria for the histological 
diagnosis of the bone tumours were those of the 2013 
WHO Classification of Tumours of Soft Tissue and Bone 
[27]. Samples were derived from biopsies and resection 
specimens fixed in 10% buffered formalin and decalcified 
in 5% nitric acid. Histology was assessed using a Nikon 
Eclipse 80i microscope.
Immunohistochemistry
5  μm sections of formalin-fixed paraffin-embedded tis-
sue were cut and then stained by an indirect immunoper-
oxidase technique using chemMate Envision (Dako, UK). 
After blocking endogenous peroxidase, sections were 
incubated with the monoclonal antibody VS38C (Dako, 
UK) with antigen unmasking pretreatment. Antigens 
were detected by incubation with labelled polymer and 
diaminobenzidine. Sections of myeloma were employed 
as a positive control. Negative controls consisted of sec-
tions which were incubated with normal mouse IgG1 (10 
or 20 μg/mL, Sigma-Aldrich, Dorset, UK) substituted for 
the monoclonal antibody. The VS38c staining was scored 
as strong or weak relative to the positive control. Where 
the majority of lesional cells were not stained with VS38c, 
an assessment of the percentage of VS38-positive cells 
relative to the total number of (lesional) cells was noted.
Expression of VS38c in MG63 and Sa0S2 cells
MG63 and SAOS2 human osteosarcoma cells were cul-
tured in Iscove’s Modified Dulbecco’s Medium (Sigma-
Aldrich, Dorset, UK) supplemented with 10% fetal calf 
serum [28]. To determine expression of VSC38c, cells 
Table 1 VS38c staining of  benign and  malignant bone 
tumours/tumour-like lesions
(), number of cases







 Giant-cell rich (1)








Chondromyxoid  fibromaa (3)
Atypical cartilaginous tumour/Chondrosarcoma, Grade I (12)
Chondrosarcoma, Grade II/III (8)
Ewing  sarcomaa (16)
Giant cell tumour of bone (12)
Aneurysmal bone cyst (4)





Langerhans cell  histiocytosisa (4)
Fracture (2)
Myositis ossificans (2)
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were plated at either low  (105 cells) or high  (106 cells) 
density in a 6 well plate and allowed to adhere overnight. 
Cells were then treated for 24 h in the presence of either 
cisplatin (1 µg/mL), actinomycin D (10 µg/mL) or vehi-
cle control. Cultures were fixed in formalin and stained 
as above by immunohistochemistry with the antibody 
VS38c.
Results
VS38c staining of normal bone and cartilage
Strong cytoplasmic staining of osteoblasts with VS38c 
was noted in compact and cancellous woven and lamellar 
bone in areas of bone remodelling (Fig.  1). A few oste-
ocytes in woven bone and a few marrow stromal cells 
and flattened bone lining cells were also weakly VS38c 
positive. Osteoclasts and fat cells in bone, fibroblasts in 
periosteal dense connective tissue, and endothelial cells/
smooth muscle cells in blood vessels were negative for 
VS38c. Chondrocytes in hyaline articular cartilage and in 
the reserve and proliferating zones of growth plate carti-
lage were unstained; hypertrophic and mineralizing car-
tilage cells in the growth plate stained with VS38c.
VS38c staining of osteosarcoma and other bone‑forming 
tumours and tumour‑like lesions
Tumour cells in all high-grade osteoblastic osteosar-
comas (Fig.  2a), as well as small cell and telangiectatic 
(Fig.  2b) sub-types strongly stained for VS38c; tumour 
cells in chondroblastic and fibroblastic areas of high-
grade osteosarcoma were also strongly stained by VS38c. 
VS38c also strongly stained osteogenic tumour cells in 
intramedullary low-grade osteosarcoma and parosteal 
osteosarcoma. In other primary bone-forming tumours, 
osteoid osteoma and osteoblastoma, there was also 
strong VS38c staining of osteoblasts lining the surface of 
woven bone; some newly formed woven bone trabeculae 
in these lesions also showed VS38c staining of osteocytes. 
In four cases of fibrous dysplasia, there was strong VS38c 
staining of mononuclear stromal cells in the intertra-
becular fibrous tissue, the remaining cases showing little 
(<10%) or no staining. In osteofibrous dysplasia, VS38c 
strongly stained plump osteoblasts rimming woven bone 
and stromal cells in the fibrous stroma. Osteoblasts in 
reactive woven bone in fracture callus and myositis ossifi-
cans were also strongly VS38c positive.
VS38c staining of other primary bone tumours
No staining or weak staining of a few (<10%) cartilage 
cells was noted with VS38c in benign cartilage tumours 
including enchondroma, osteochondroma and chon-
dromyxoid fibroma; some cellular enchondromas of 
Fig. 1 Immunohistochemistry with monoclonal antibody VS38c 
showing strong staining of osteoblasts in remodelling cancellous 
bone. (original magnification ×200)
Fig. 2 Immunohistochemistry with monoclonal antibody VS38c showing strong staining of osteoid-forming tumour cells in: (a) high-grade osteo-
blastic osteosarcoma and (b) telangiectatic osteosarcoma. (original magnification: a ×200; b ×100)
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the hand, however, showed more prominent staining 
of cartilage cells. In contrast, VS38c strongly stained 
chondroblasts in chondroblastoma. Atypical cartilagi-
nous tumour/chondrosarcoma grade 1 showed a similar 
pattern of VS38c staining to that seen in most enchon-
dromas, but malignant cells in high-grade chondrosar-
comas strongly and diffusely stained with VS38c (Fig. 3a, 
b). In dedifferentiated chondrosarcoma, the low-grade 
chondrosarcoma component showed little staining with 
VS38c whereas the high-grade sarcoma component was 
strongly stained (Fig. 3c).
In giant cell tumour of bone, mononuclear cells 
strongly stained with VS38c but osteoclast-like giant cells 
were negative (Fig. 4a). A similar pattern of staining was 
noted in non-ossifying fibroma and aneurysmal bone 
cyst where reactive woven bone and scattered fibroblastic 
cells in the cyst wall were also stained by VS38c.
All tumor cells in primary high-grade undifferenti-
ated spindle cell/pleomorphic sarcoma of bone stained 
strongly with VS38c. Ten of 16 cases of Ewing sarcoma 
were also strongly and diffusely stained with VS38c, 
(Fig.  4b), but six cases showed staining of a few (<10%) 
cells. Most chordomas were VS38c-negative but two 
cases showed weak staining of a few (<10%) cells. VS38c 
strongly stained adamantinomas in both epithelial and 
mesenchymal components.
VS38c staining of osteosarcomas receiving neoadjuvant 
chemotherapy
Strong VS38c staining of osteosarcoma cells was noted 
in all pre-treatment biopsies of the 25 cases of osteo-
sarcoma that had received pre-operative neoadjuvant 
therapy. VS38c strongly stained areas containing residual 
viable tumour in resection specimens of these treated 
osteosarcomas (Fig.  5). Absence of VS38c staining was 
noted in areas of tumour necrosis where there was only 
amorphous cellular debris or ghost cells i.e. where nucle-
ated tumour cells could not be identified morphologi-
cally (Figs.  5, 6a). In morphologically necrotic areas of 
tumour, a variable number of cells with pyknotic nuclei 
stained with VS38c (Fig.  6b). In some tumours, there 
were scattered atypical cells with vacuolated cytoplasm 
Fig. 3 Immunohistochemistry with monoclonal antibody VS38c showing: a strong staining of cartilage tumour cells in high-grade chondrosar-
coma; b absence of staining of cartilage tumour cells in low-grade chondrosarcoma; c in dedifferentiated chondrosarcoma absence of staining in 
the low-grade chondrosarcoma component and strong staining in the dedifferentiated pleomorphic sarcoma component. (original magnification: 
a ×400; b ×400; c ×100)
Fig. 4 Immunohistochemistry with monoclonal antibody VS38c showing: a staining of mononuclear cells but not giant cells in giant cell tumour of 
bone; and b staining of tumour cells in Ewing sarcoma. (original magnification: a ×400; b ×400)
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Fig. 5 Immunohistochemistry with monoclonal antibody VS38c of an osteosarcoma that had received neoadjuvant therapy showing: a low and b 
high-power views of VS38c staining of residual viable tumour (right) and absence of staining in necrotic areas of tumour (left) (original magnifica-
tion: a ×100; b ×400)
Fig. 6 Immunohistochemistry with monoclonal antibody VS38c of an osteosarcoma that had received neoadjuvant therapy showing in necrotic 
areas of the tumour: a absence and b variable VS38c staining of cells with pyknotic nuclei and c absence and d variable staining with VS38c of 
atypical cells with vacuolated cytoplasm (original magnification: a ×200; b ×200; c ×400; d ×400)
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and bizarre homogenization of nuclear chromatin; most 
of these cells were negative for VS38c (Fig. 6c) but a few 
were noted to be VS38c positive (Fig. 6d).
VS38c staining of cultured osteosarcoma cells treated 
by cisplatin and actinomycin D
Control cultures of MG63 and Sa0S2 osteosarcoma cells 
contained viable tumour cells that strongly expressed 
VS38c (Fig.  7a). In parallel cultures to which cisplatin 
and actinomycin D had been added, there was necrosis of 
tumour cells which did not stain for VS38c (Fig. 7b).
Discussion
Osteosarcoma is the most common primary malig-
nant tumour of bone. Histological diagnosis of osteo-
sarcoma is based on the identification of cytologically 
malignant tumour cells that form osteoid/bone. These 
matrix protein-producing malignant cells ultrastructur-
ally contain numerous ribosomes and rER. In this study, 
we have shown that tumour cells in all high-grade and 
low-grade osteosarcomas are stained by the monoclo-
nal antibody VS38c which recognises the CLIMP-63 
protein on rER. Although absence of VS38c expression 
effectively excludes the diagnosis of osteosarcoma, the 
diagnostic specificity of this antibody is limited because, 
as noted previously [5], VS38c also stains other bone 
tumours. Absence of staining with VS38c was noted in 
cultures of actinomycin D/cisplatin-treated osteosar-
coma cells and in necrotic areas of (post-neoadjuvant 
therapy) osteosarcoma specimens, a finding which may 
be useful in evaluating percentage tumour necrosis in 
osteosarcoma.
In this study we characterised the pattern of VS38c 
staining in primary benign and malignant bone 
tumours. In addition to osteosarcoma and other benign 
bone-forming tumours, VS38c strongly stained other 
high-grade primary malignant bone tumours, including 
undifferentiated spindle-cell/pleomorphic sarcoma and 
Grade II/III chondrosarcoma. VS38c staining was also 
noted in most Ewing sarcomas, although the number of 
stained cells was highly variable. Atypical cartilaginous 
tumour/chondrosarcoma grade 1 and chordoma were 
either negative or showed little staining with VS38c. In a 
number of giant-cell rich lesions of bone, including giant-
cell tumour, non-ossifying fibroma, chondroblastoma 
and aneurysmal bone cyst, VS38c strongly stained mono-
nuclear cells but not osteoclastic giant cells. VS38c stain-
ing of such a wide range of bone tumours clearly limits its 
diagnostic specificity but, given its strong and consistent 
staining of osteosarcoma, it may be useful as a highly sen-
sitive if not specific positive marker of this tumour.
Although a number of factors, (e.g. tumour site, size 
and histological subtype) influence disease survival in 
osteosarcoma, the extent of chemotherapy-induced 
necrosis has been shown to correlate most strongly with 
prognosis. Multi-drug neoadjuvant chemotherapy for 
high-grade osteosarcoma is now routinely employed and 
systematic pathological evaluation of the resection speci-
men of a treated osteosarcoma has been shown to yield 
important prognostic information about the chemother-
apeutic response and to provide a guide as to whether 
adjuvant chemotherapy is required [16–19]. In cases 
where chemotherapy-induced necrosis is 90% or more, 
the 5  year disease free survival is more than 80% [27, 
29–36]. Loss of ribosomes and rER is seen in necrotic 
tumour cells [10, 11]. We noted that, in osteosarcoma 
specimens that had received neoadjuvant therapy, VS38c 
staining was strongly positive in areas of residual viable 
tumour but largely absent in morphologically necrotic 
areas of tumour; this pattern of staining was reflected in 
osteosarcoma cell cultures, where VS38c strongly stained 
viable but not necrotic tumour cells.
Fig. 7 Immunohistochemistry with monoclonal antibody VS38c showing (a) staining of cultured SAOS2 osteosarcoma cells and (b) SAOS2 cells 
treated with cisplatin. (original magnification: a ×400; b ×400)
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Qualitative assessment of the percentage area of 
tumour necrosis in pathological specimens of osteo-
sarcoma is believed to correlate well with quantitative 
morphometric analysis [15–19]. However, there are no 
studies, to our knowledge, which have proved that mor-
phological assessment of tumour necrosis in osteosar-
coma is accurate. Most histopathologists rely on the 
identification of cytoplasmic and nuclear alterations 
indicative of cell death, such as pyknosis, karyorrhexis 
and karyolysis, to determine tumour necrosis in chemo-
therapy-treated osteosarcomas. Necrotic areas of tumour 
often contain ghost cells which show a variable degree 
of loss of nuclear and cytoplasmic detail. However, irre-
versible cell death or necrosis is difficult to distinguish 
morphologically from reversible degenerative change 
or apoptosis affecting individual cells or small groups of 
cells. Preoperative neo-adjuvant chemotherapy of osteo-
sarcomas not only results in necrosis, but also changes 
in the tumour stroma which maybe partly calcified, con-
tain hypermineralised bone or areas of reparative fibro-
sis, neovascularisation and inflammation [22–24, 26]. A 
major challenge to the surgical pathologist is the inter-
pretation of atypical cells containing vacuolated cyto-
plasm and hyperchromatic nuclei with smudged or 
clumped chromatin found in some post-treatment 
osteosarcoma specimens. These atypical cells are often 
found in areas where there is not only necrosis but also 
fibrosis and it can be difficult to determine morphologi-
cally whether such cells are apoptotic/necrotic or viable. 
We found that most of these cells were VS38c negative, 
indicating that they did not contain rER. However, a few 
of these cells were VS38c positive. Cells with pyknotic 
nuclei are not uncommonly seen in areas of tumour 
necrosis in post-chemotherapy osteosarcoma specimens. 
Pyknosis is a nuclear feature seen in both apoptotic and 
necrotic cells and we noted that some tumour cells with 
pyknotic nuclei were VS38c positive; this indicates that 
such cells contain rER and that they are thus potentially 
capable of protein production, a feature characteristic of 
viable tumour cells.
In conclusion, our findings indicate that VS38c is a 
highly sensitive but not specific diagnostic marker for 
osteosarcoma. VS38c staining was seen in other pri-
mary benign and malignant bone tumours but it was not 
prominent in some low-grade tumours such as atypical 
cartilaginous tumour. VS38c staining outlined areas of 
residual viable tumour in post-chemotherapy osteo-
sarcoma specimens and aided assessment of percent-
age tumor necrosis. However, although there was little 
or no VS38c staining in most areas of tumour necrosis 
in osteosarcoma specimens, there was variable stain-
ing of atypical cells with clumped chromatin and vacu-
olated cytoplasm and cells with pyknotic nuclei. The 
status of these VS38c positive cells in these necrotic areas 
is uncertain and more studies are needed to determine 
whether the morphological assessment of percentage 
tumour necrosis truly reflects the extent of viable and 
necrotic tumour in osteosarcoma specimens.
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